Trans-platinum(II) complexes with cyclohexylamine as expectator ligand induce necrosis in tumour cells by inhibiting DNA synthesis and RNA transcription

Clinical and Translational Oncology

Volumn 9, Issue 8, 2007, Pages 521-530

  Cepero, V ^a   Garcia Serrelde B ^a   Moneo, V ^a   Blanco, F ^a   Gonzalez Vadillo A M ^b   Alvarez Valdes A ^b   Navarro Ranninger, C ^b   Carnero, A ^a  

^a Centro Nacional de Investigaciones Oncológicas   (Spain)

^b UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

Author keywords

Antitumour drugs; Cell cycle; Cytotoxic activity; Platinum anticancer drugs; Transplatin

Indexed keywords

CISPLATIN; DOXORUBICIN; ETOPOSIDE; PLATINUM COMPLEX; PROTEIN P53; TRANSDIMETHYLAMINE(CYCLOHEXYLAMINE)DICHLORODIHYDROXYPLATINUM; TRANSDIMETHYLAMINE(CYCLOHEXYLAMINE)DICHLOROPLATINUM; TRANSPLATIN; ANTINEOPLASTIC AGENT; DICHLORO(CYCLOHEXYLAMINE)(DIMETHYLAMINE)PLATINUM(II); DIHYDROXO(CYCLOHEXYLAMINE)(DIMETHYLAMINE)PLATINUM(II); DNA; LIGAND; MESSENGER RNA; ORGANOMETALLIC COMPOUND; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER RESISTANCE; CELL CYCLE ARREST; CELL CYCLE S PHASE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA DAMAGE; DNA SYNTHESIS INHIBITION; DRUG CYTOTOXICITY; DRUG DNA BINDING; DRUG EFFICACY; DRUG SYNTHESIS; NONHUMAN; RNA TRANSCRIPTION; TRANSCRIPTION TERMINATION; TUMOR CELL DESTRUCTION; TUMOR CELL LINE; BIOSYNTHESIS; CELL AGING; CELL CYCLE; DOSE RESPONSE; DRUG EFFECT; GENETIC TRANSCRIPTION; HUMAN; METABOLISM; NECROSIS; SYNTHESIS;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL AGING; CELL CYCLE; CELL LINE, TUMOR; DNA; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; LIGANDS; NECROSIS; ORGANOMETALLIC COMPOUNDS; ORGANOPLATINUM COMPOUNDS; RNA, MESSENGER; TRANSCRIPTION, GENETIC;

EID: 38449093279     PISSN: 1699048X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12094-007-0096-2     Document Type: Article

References (54)

1. Lippert B (1999) 30 years of cisplatin - chemistry and biochemistry of a leading anticancer drug. Verlag HCA, Basel
2. Giaccone G (2000) Clinical perspectives on platinum resistance. Drugs 59[Suppl]:4-9
3. Kelland LR, Farrell N (2000). Platinum-based drugs in cancer therapy. In: Teicher BA (ed.) Cancer drug discovery and development. Humana Press, Clifton, UK
4. Cohen SM, Lippard SJ (2001) Cisplatin: From DNA damage to cancer chemotherapy. Prog Nucleic Acid Res Mol Biol 67:93-130
5. Zamble BD, Lippard SJ (1995) Cisplatin and DNA repair in cancer chemotherapy. Trends Biochem Sci 20:435-439
6. Trimmer EE, Essigmann JM (1999) Cisplatin. Essays Biochem 34:191-211
7. Brabec V, Kasparkova J (2002) Molecular aspects of resistance to antitumor platinum drugs. Drug Resist Updates 5:147-161
8. Zhang CX, Lippard SJ (2003) New metal complexes as potential therapeutics. Curr Opin Chem Biol 7:481-489
9. Heiger-Bernays WJ, Essigmann JM, Lippard SJ (1990) Effects of the antitumor drug cis-diamminedichloroplatinum(II) and related platinum complexes on eukaryotic DNA replication. Biochemistry 29:8461-8466
10. Farrell N, Kelland LR, Roberts JD, Van Beusichem M (1992) Activation of the trans geometry in platinum antitumor complexes. A survey of the cytotoxicity of trans complexes containing planar ligands in Murine L1210 and human tumor panels and studies on their mechanism of action. Cancer Res 52:5065-5072
11. Kelland LR, Barnard CF, Evans IG et al (1995) Synthesis and in vitro antitumor activity of a series of trans platinum antitumor complexes. J Med Chem 38:3016-3024
12. Montero EI, Diaz S, Gonzalez-Vadillo AM et al (1999). Preparation and characterization of novel trans-[PtCl(2)(amine)(isopropylamine)] compounds: Cytotoxic activity and apoptosis induction in ras-trans formed cells. J Med Chem 42:4264-4268
13. Natile G, Coluccia M (2001) Current status of trans-platinum compounds in cancer therapy. Coord Chem Rev 216-217:383-410
14. Perez JM, Fuertes MA, Alonso C, Navarro-Ranninger C (2000) Current status of the development of trans-platinum antitumor drugs. Crit Rev Oncol Hematol 35:109-120
15. Perez JM, Montero EI, Gonzalez AM et al (2000) X-ray structure of cytotoxic trans-[Pt-Cl(2)(dimethylamine)(isopropylamine)]: Interstrand cross-link efficiency, DNA sequence specificity, and inhibition of the B-Z trans ition. J Med Chem 43:2411-2418
16. Riccardi A, Meco D, Ferlini C et al (2001) In vitro and in vivo antitumor activity of the novel trinuclear platinum complex BBR 3464 in neuroblastoma. Cancer Chemother Pharmacol 47:498-504
17. Servidei T, Ferlini C, Riccardi A et al (2001). The novel trinuclear platinum complex BBR3464 induces a cellular response different from cisplatin. Eur J Cancer 37:930-938
18. Van Beusichem M, Farrell N (1992) Activation of the trans geometry in platinum antitumor complexes. Synthesis, characterisation and biological activity of complexes with planar ligands pyridine, N-methylimidazole, thiazole and quinoline. The crystal and molecular structure of trans-dichlorobis(thiazole)platinum(II). Inorg Chem 31:634-639
19. Farrell N (1996) Current status of structure-activity relationships of platinum anticancer drugs. Activation of the trans geometry. Metal Ions Biol Sys 32:603-639
20. Zou Y, Van Houten B, Farrell N (1993) Ligand effects on platinum binding to DNA. A comparison of DNA binding properties for cis-and trans-[PtCl2(amine)2] (amine = NH3, pyridine). Biochemistry 32:9632-9638
21. Brabec V (2002) DNA modifications by antitumor platinum and ruthenium compounds: Their recognition and repair. Progr Nucleic Acid Res Mol Biol 71:1-68
22. Farrell N, Povirk LF, Dange Y et al (2004) Cytotoxicity, DNA strand breakage and DNA-protein crosslinking by a novel trans platinum compound in human A2780 ovarian and MCF-7 breast carcinoma cells. Biochem Pharmacol 68:857-866
23. Perez JM, Kelland LR, Montero EI et al (2003) Antitumor and cellular pharmacological properties of a novel platinum(IV) complex: trans-[Pt-Cl(2)(OH)(2)(dimethylamine) (isopropylamine)]. Mol Pharmacol 63:933-944
24. Bierbach U, Qu Y, Hambley TW et al (1999) Synthesis, structure, biological activity and DNA binding of platinum(II) complexes of the type trans-[PtCl2(NH3)L] (L = planar nitrogen base). Effect of L and cis/ trans isomerism on sequence specificity and unwinding properties observed in globally platinated DNA. Inorg Chem 38:3535-3542
25. Najajreh Y, Pérez JM, Navarro-Ranninger C, Gibson D (2002) Novel soluble cationic trans diaminedichloroplatinum(II) complexes that are active against cisplatin resistant ovarian cancer cell lines. J Med Chem 45:5189-5195
26. Barnard CFJ, Raynaud FY, Kelland LR (1999) In: Clarke MJ, Sadler PJ (eds) Metallopharmaceuticals I: DNA Interactions. Springer, Berlin, pp. 45
27. Kelland LR, Abel G, McKeage MJ et al (1993) Preclinical antitumor evaluation of bis-acetatoammine-dichloro-cyclohexylamine platinum(IV): an orally active platinum drug. Cancer Res 53:2581-2586
28. González-Vadillo AM, Álvarez-Valdés A, Moneo V et al (2007) Structure-activity relationship of new trans platinum(II) and (IV) complexes with cyclohexylamine. Interference with cell cycle progression and induction of cell death. J Inorg Biochem 101:551-558
29. Moneo V, Serelde BG, Leal JF et al (2007) Levels of p27kip1 determine Aplidin sensitivity. Mol Cancer Ther 6:1310-1316
30. Pucci B, Kasten M, Giordano A (2000) Cell cycle and apoptosis. Neoplasia 2:291-299
31. Siddick ZH (2003) Cisplatin: Mode of cytotoxic action and molecular basis of resistance. Oncogene 22:7265-7279
32. Campisi J (2005) Senescent cells, tumor suppression, and organismal aging: Good citizens, bad neighbors. Cell 120:513-522
33. Carnero A (2007) Cellular senescence as a target in cancer control. Curr Cancer Ther Rev 3:7-15
34. Roninson IB, Broude EV, Chang BD (2001) If not apoptosis, then what? Treatment-induced senescence and mitotic catastrophe in tumor cells. Drug Resist Updat 4:303-313
35. Carnero A, Blanco C, Blanco F et al (2003) Exploring cellular senescence as a tumor suppressor mechanism. Revista de Oncologia 5:249-265
36. Shay JW, Roninson IB (2004) Hallmarks of senescence in carcinogenesis and cancer therapy. Oncogene 23:2919-2933
37. Wyllie AH (1993) Apoptosis (the 1992 Frank Rose Memorial Lecture). Br J Cancer 67:205-208
38. Wyllie AH, Kerr JF, Currie AR (1980) Cell death: The significance of apoptosis. Int Rev Cytol 68:251-306
39. Hickman JA (1992) Apoptosis induced by anticancer agents. Cancer Metastasis Rev 11:121-139
40. Blanc C, Devereux QL, Krajewski S et al (2000) Caspase-3 is essential for procaspase-9 processing and cisplatin-induced apoptosis of MCF-7 breast cancer cells. Cancer Res 60:4386-4390
41. Montero EI, Perez JM, Schwartz A et al (2002) Apoptosis induction and DNA interstrand crosslink formation by cytotoxic trans-[PtCl2(NH(CH3)2)(NHCH(CH3)2)]: Cross-linking between d(G) and complementary d(C) within oligonucleotide duplexes. ChemBioChem 3:61-67
42. Pantoja E, Gallipoli A, van Zutphen S et al (2006) In vitro antitumor activity and interaction with DNA model bases of cis-[PtCl2(iPram)(azole)] complexes and comparison with their trans analogues. Inorg Chim Acta 359:4335-4342
43. Moneo V, Serelde BG, Fominaya J et al (2007) Extreme sensitivity to Yondelis(R) (Trabectedin, ET-743) in low passaged sarcoma cell lines correlates with mutated p53. J Cell Biochem 100: 339-348
44. Coluccia M, Nassi A, Boccarelli A et al (1999) In vitro antitumour activity and cellular pharmacological properties of the platinum-iminoether complex trans-[PtCl2[E-HN=C(OMe)Me]2]. Int J Oncol 15:1039-1044
45. Coluccia M, Nassi A, Boccarelli A et al (1999) In vitro and in vivo antitumour activity and cellular pharmacological properties of new platinum-iminoether complexes with different configuration at the iminoether ligands. J Inorg Biochem 77:31-35
46. Coluccia M, Nassi A, Loseto F et al (1993) A trans-platinum complex showing higher antitumor activity than the cis congeners. J Med Chem 36:510-512
47. Ormerod MG, O'Neill C, Robertson D et al (1996). cis-Diamminedichloroplatinum(II)-induced cell death through apoptosis in sensitive and resistant human ovarian carcinoma cell lines. Cancer Chemother Pharmacol 37:463-471
48. O'Neill CF, Ormerod MG, Robertson D et al (1996) Apoptotic and non-apoptotic cell death induced by cis and trans analogues of a novel ammine(cyclohexylamine) dihydroxodichloroplatinum(IV) complex. Br J Cancer 74:1037-1045
49. Orlandi L, Colella G, Bearzatto A et al (2001) Effects of a novel trinuclear platinum complex in cisplatin-sensitive and cisplatin-resistant human ovarian cancer cell lines: Interference with cell cycle progression and induction of apoptosis. Eur J Cancer 37:649-659
50. Pinto AL, Lippard SJ (1985) Binding of the antitumor drug cis-diamminedichloroplatinum(II) (cisplatin) to DNA. Biochim Biophys Acta 780:167-180
51. O'Connor PM, Fan S (1996) DNA damage checkpoints: Implications for cancer therapy. Prog Cell Cycle Res 2:165-173
52. Eliopoulos AG, Kerr DJ, Herod J et al (1995) The control of apoptosis and drug resistance in ovarian cancer: Influence of p53 and Bcl-2. Oncogene 11:1217-1228
53. Hagopian GS, Mills GB, Khokhar AR et al (1999) Expression of p53 in cisplatin-resistant ovarian cancer cell lines: Modulation with the novel platinum analogue (1R, 2R-diaminocyclohexane)(trans -diacetato)(dichloro)-platinum(IV). Clin Cancer Res 5:655-663
54. Nguyen HN, Sevin BU, Averette HE et al (1993) Cell cycle perturbations of platinum derivatives on two ovarian cancer cell lines. Cancer Invest 11:264-275